title: More on cutaneous reactions to recombinant cytokine therapy.
authors.forename: F A
authors.initials: FA
authors.lastname: Le Gal
authors.forename: C
authors.initials: C
authors.lastname: Paul
authors.forename: P
authors.initials: P
authors.lastname: Chemaly
authors.forename: L
authors.initials: L
authors.lastname: Dubertret
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D007371:Interferon-gamma / Q000009:adverse effects*; D007376:Interleukin-2 / Q000009:adverse effects; D008545:Melanoma / Q000473:pathology / Q000556:secondary / Q000628:therapy; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy; D014820:Vitiligo / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma